Victory Capital Management Inc Galectin Therapeutics Inc Transaction History

Victory Capital Management Inc

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Aug 07, 2020	SELL	$1.66 - $3.15 $12,269 - $23,281	-7,391 Closed	0 $0
Q1 2020 May 04, 2020	SELL	$1.51 - $3.0 $252 - $501	-167 Reduced 2.21%	7,391 $14,000
Q4 2019 Feb 04, 2020	SELL	$2.79 - $4.32 $1,420 - $2,198	-509 Reduced 6.31%	7,558 $20,000
Q3 2019 Nov 12, 2019	BUY	$3.0 - $4.05 $24,201 - $32,671	8,067 New	8,067 $30,000

9.69M

1.16M

1.98M

Ticker GALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,426,000
Market Cap $73.7M
Description
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial f...

Get notified when there are updates to the investment portfolio of Victory Capital Management Inc, based on Form 13F filings with the SEC.

Stay updated on Victory Capital Management Inc with notifications on news.